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Pharmaceutical tabletsAbstract Simple and selective HPTLC methods were developed for the simultaneous determina-
tion of the antihypertensive drugs; carvedilol and hydrochlorothiazide in their binary mixture (Mix-
ture I) and amlodipine besylate, valsartan, and hydrochlorothiazide in their combined ternary
formulation (Mixture II). Effective chromatographic separation was achieved on Fluka TLC plates
20 · 20 cm aluminum cards, 0.2 mm thickness through linear ascending development. For Mixture
I, the mobile phase composed of chloroform–methanol in the ratio 8:2 v/v. Detection was per-
formed at 254 nm for both carvedilol and hydrochlorothiazide. For Mixture II, the mobile phase
was chloroform–methanol–ammonia in the volume ratio 8:2:0.1. Detection was performed at
254 nm for valsartan and hydrochlorothiazide, and at 365 nm for amlodipine. Quantiﬁcation was
based on spectrodensitometric analysis. Analytical performance of the proposed HPTLC proce-
dures was statistically validated with respect to linearity, ranges, precision, accuracy, speciﬁcity,
robustness, detection and quantiﬁcation limits. The linearity ranges were 0.05–1.0 and 0.1–
2.0 lg/spot for carvedilol and hydrochlorothiazide, respectively in Mixture I, 0.1–2.0, 0.1–2.0 and
0.2–4.0 lg/spot for amlodipine, hydrochlorothiazide and valsartan, respectively in Mixture II, with
correlation coefﬁcients >0.9992. The validated HPTLC methods were applied to the analysis of the
cited antihypertensive drugs in their combined pharmaceutical tablets. The proposed methods
conﬁrmed peak identity and purity.
ª 2014 Production and hosting by Elsevier B.V. on behalf of Faculty of Pharmacy, Cairo University.
Open access under CC BY-NC-ND license.1. Introduction
Carvedilol (CRV) (Fig. 1), chemically known as (2RS)-1-(9H-
carbazol-4-yloxy)-3-[[2-(2-ethoxyphenoxy)ethyl]amino]propan-
2-ol,1 is a non-cardioselective beta blocker. It has vasodilating
properties, which are attributed mainly to its alpha-1 blocking
OH3CO
N
H
OH
O
N
H
N
H
NH
S
O O
Cl
S
H2N
O O
H
NH3C
O
NH2
O
O
H3CO
O
CH3
Cl
S
O
O
OH
N
N
NN
HN
H3C
COOH
O
CH3H3C
CRV
HCT
AML
VAL
Figure 1 Chemical structures of carvedilol (CRV), hydrochlorothiazide (HCT), amlodipine besylate (AML) and valsartan (VAL).
226 R.A. Shaalan et al.activity; at higher doses, calcium channel blocking activity may
contribute. CRV is used in the management of hypertension,
angina pectoris and as an adjunct to standard therapy in symp-
tomatic heart failure.2 Hydrochlorothiazide (HCT) (Fig. 1),
chemically known as 6-chloro-3,4-dihydro-2H-1,2,4-benzothi-
adiazine-7-sulfonamide-1,1-dioxide,1 is a moderately potent
diuretic. HCT is used in the treatment of hypertension either
alone or with other antihypertensives. It is also used to treat
edema associated with heart failure and with renal and hepatic
disorders.2 The ﬁxed dose combination of CRV and HCT has
been used for the treatment of essential hypertension particu-
larly if with the monotherapy no sufﬁcient blood pressure
lowering can be achieved.3 The simultaneous determination
of CRV and HCT in their binary combination was addressed
in few analytical reports. These reports proposed several spec-
trophotometric4,5 and RP-HPLC with UV detection meth-
ods.4,6 A stability-indicating HPLC method was recently
published.7 The fact that up till now the simultaneous HPTLCdetermination of this binary mixture has been reported in the
literature in only one report8 has encouraged us to develop this
work.
Amlodipine besylate (AML) (Fig. 1), chemically known as
3-ethyl-5-methyl2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-
1,4-dihydro-6-methylpyridine-3,5-dicarboxylate benzenesulph-
onate,2 is a dihydropyridine calcium channel blocker used in
the treatment of hypertension and angina pectoris.2 Valsartan
(VAL) (Fig. 1), chemically known as N-[p-(o-1H-tetrazol-5-
ylphenyl)benzyl]-N-valeryl-L-valine,2 is an angiotensin II
receptor antagonist used in the management of hypertension,
to reduce cardiovascular mortality in myocardial infarction
patients and in the management of heart failure.2 In 2009,
the US Food and Drug Administration (FDA) and the
European Medicines Agency approved a triple ﬁxed-dose com-
bination of AML, VAL and HCT. It was found that the use of
this triple combination was generally more effective in
reducing blood pressure and providing overall blood pressure
Table 1 Linear regression data for calibration plots of the analyzed drugs using the proposed HPTLC methods.
Parameter MIX I MIX II
CRV HCT AML HCT VAL
Wavelength (nm) 254 254 365 254 254
Rf 0.62 ± 0.06 0.37 ± 0.03 0.70 ± 0.04 0.29 ± 0.03 0.07 ± 0.02
Concentration range (lg/spot) 0.05–1 0.1–2 0.1–2 0.1–2 0.2–4
Intercept (a) 86.54 259.72 415.55 336.15 785.76
Sa
a 23.15 41.57 169.19 52.24 128.16
Slope (b) 8408.28 4492.48 6260.78 3974.91 3603.90
Sb
b 45.35 40.38 127.59 55.53 53.80
RSD% of slope 0.54 0.90 2.04 1.39 1.49
r 0.9999 0.9997 0.9992 0.9992 0.9993
Sy/x
c 50.42 88.69 253.10 108.38 241.77
Fd 34376.58 12377.49 2407.84 5123.69 4487.29
Signiﬁcance F 8.01 · 1016 4.76 · 1014 1.03 · 106 1.62 · 1012 7.44 · 1010
LODe (lg/spot) 0.01 0.03 0.02 0.03 0.07
LOQf (lg/spot) 0.04 0.08 0.07 0.09 0.18
a Standard deviation of the intercept.
b Standard deviation of the slope.
c Standard deviation of residuals.
d Variance ratio, equals the mean of squares due to regression divided by the mean of squares about regression (due to residuals).
e Limit of detection.
f Limit of quantiﬁcation.
Figure 2 3D chromatogram of 0.1, 0.2, 0.5, and 1 lg/spot CRV and 0.1, 0.2, 0.5, and 1 lg/spot HCT duplicate spot for each
concentration detected at 254 nm.
HPTLC methods for determination of antihypertensive mixtures 227control than the dual combination therapies regardless of age,
race, gender, ethnicity, or hypertension severity.9,10 Few
reports can be found in the scientiﬁc literature for the simulta-
neous determination of AML, VAL and HCT. These reports
presented spectrophotometric,11–14 HPTLC14–16 and several
HPLC methods.14–20This work includes HPTLC determination of the two
antihypertensive mixtures namely; CRV–HCT binary mixture
and AML–HCT–VAL ternary mixture. The objective of the
work was directed toward the development, validation and
application of simple and easy to use methods for routine
determination of the studied drugs in their formulations. As
Figure 3 3D chromatogram of 0.1, 0.2, 0.5, 1, 1.50, and 2 lg/spot AML, 0.1, 0.2, 0.5, 1, 1.50, and 2 lg/spot HCT and 0.4, 0.8, 1, 2, 3,
and 4 lg/spot VAL duplicate spot for each concentration at (A) 254 nm and (B) 365 nm.
228 R.A. Shaalan et al.method validation is an important requirement in analytical
method development, the proposed method has been validated
following the guidelines of the USP and ICH.
2. Experimental
2.1. Instrumentation
CAMAG Linomat TLC-Applicator. A CAMAG Linomat syr-
inge (100 lL) was used for the application of solutions onto sil-
ica gel plates. The plates were developed in CAMAG twintrough chromatographic tanks (15 · 20 · 30 cm), and scanned
densitometrically using CAMAG TLC-Scanner 3 (Version
4.06), Supported with deuterium, and tungsten lamp and inter-
faced to an IBM computer loaded with CAMAG-TLC-Soft-
ware (CATS).
2.2. Materials and reagents
CRV was kindly supplied by Chemipharm Pharmaceutical
Industries, 6th October City, Egypt. HCT was kindly donated
by Pharco Pharmaceuticals Co., Alexandria, Egypt. AML was
Table 2 Precision and accuracy for determination of the analyzed drugs in bulk form using the proposed HPTLC methods.
Drug CRV HCT
Mix I
Nominal value (lg/spot) 0.2 0.5 1 0.2 0.5 1
Within-day
Found ± SDa (lg/spot) 0.2022 ± 0.0035 0.5006 ± 0.0055 0.9954 ± 0.0020 0.2027 ± 0.0039 0.5099 ± 0.0054 0.9940 ± 0.0014
RSD(%)b 1.73 1.10 0.20 1.92 1.06 0.14
Er(%)c 1.10 0.12 0.46 1.35 1.98 0.6
Between-day
Found ± SDa (lg/spot) 0.2034 ± 0.0014 0.5001 ± 0.0044 0.9948 ± 0.0061 0.2027 ± 0.0032 0.5039 ± 0.0070 0.9983 ± 0.0031
RSD(%)b 0.69 0.88 0.61 1.58 1.39 0.31
Er(%)c 1.7 0.02 0.52 1.35 0.78 0.17
Drug AML HCT VAL
Mix II
Nominal value (lg/spot) 0.2 0.5 1.5 0.2 0.5 1 0.8 1.5 4
Within-day
Found ± SDa (lg/spot) 0.2027 ± 0.0026 0.4966 ± 0.0026 1.5003 ± 0.0073 0.2036 ± 0.0017 0.5095 ± 0.0019 1.0079 ± 0.0017 0.8082 ± 0.0091 1.5096 ± 0.0102 3.9901 ± 0.0052
RSD(%)b 1.28 0.52 0.49 0.83 0.37 0.17 1.13 0.68 0.13
Er(%)c 1.35 0.68 0.02 1.8 1.9 0.79 1.03 0.64 0.25
Between-day
Found ± SDa (lg/spot) 0.2036 ± 0.0035 0.4987 ± 0.0057 1.5092 ± 0.0071 0.1994 ± 0.0024 0.509 ± 0.0055 1.0061 ± 0.0141 0.8015 ± 0.0069 1.5095 ± 0.0042 3.9908 ± 0.0184
RSD(%)b 1.72 1.14 0.47 1.2 1.08 1.4 0.86 0.28 0.46
Er(%)c 1.8 0.26 0.61 0.3 1.8 0.61 0.19 0.63 0.23
a Mean ± standard deviation for three determinations.
b % Relative standard deviation.
c % Relative error.
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Figure 4 Purity spectra between 200 and 400 nm for CRV (A), HCT (B), AML (C), VAL (D).
230 R.A. Shaalan et al.kindly supplied by Pﬁzer Egypt S.A.E., Cairo, Egypt, and
VAL was kindly provided by Novartis Pharma S.A.E., Cairo,
Egypt. HPLC-grade acetonitrile (Scharlau Chemie S.A.,Sentmenat, Spain), HPLC-grade methanol and chloroform
(Sigma-aldrich Chemie GmbH, Buchs, Switzerland) were used.
Pharmaceutical preparations containing the binary mixture are
Table 3 Determination of laboratory-prepared mixtures of the analyzed drugs in bulk form using the proposed HPTLC methods.
Mix 1
Nominal value (lg/
spot)
Found ± SDa (lg/spot) RSD(%)b Er(%)
c
CRV HCT CRV HCT CRV HCT CRV HCT
0.20 0.40 0.2017 ± 0.0029 0.4043 ± 0.0022 1.44 0.54 0.85 1.08
0.20 0.20 0.2020 ± 0.0013 0.2024 ± 0.0037 0.64 1.83 1 1.20
0.40 0.20 0.3996 ± 0.0013 0.1999 ± 0.0037 0.33 1.85 0.1 0.05
0.60 0.20 0.6014 ± 0.0035 0.1970 ± 0.0030 0.58 1.52 0.23 1.50
0.80 0.20 0.7961 ± 0.0033 0.1966 ± 0.0027 0.41 1.37 0.49 1.70
1.00 0.20 0.9959 ± 0.0011 0.2030 ± 0.0007 0.11 0.34 0.41 1.50
Mix 2
Nominal value (lg/
spot)
Found ± SDa (lg/spot) RSD(%)b Er(%)
c
AML HCT VAL AML HCT VAL AML HCT VAL AML HCT VAL
0.20 0.20 4.00 0.2002 ± 0.0018 0.2001 ± 0.0031 3.9972 ± 0.0132 0.90 1.55 0.33 0.10 0.05 0.07
0.10 0.30 3.20 0.1011 ± 0.0019 0.2983 ± 0.0020 3.1955 ± 0.0075 1.88 0.67 0.23 1.10 0.57 0.14
1.00 1.00 1.00 1.0015 ± 0.0025 0.9975 ± 0.0092 1.0066 ± 0.0117 0.25 0.92 1.16 0.15 0.25 0.66
0.25 0.25 1.50 0.2514 ± 0.0001 0.2506 ± 0.0027 1.5072 ± 0.0104 0.04 1.08 0.69 0.56 0.24 0.48
0.25 1.5 0.25 0.2506 ± 0.0013 1.5031 ± 0.0109 0.2515 ± 0.0016 0.52 0.73 0.65 0.24 0.21 0.60
1.50 0.25 0.25 1.4983 ± 0.0162 0.2503 ± 0.0022 0.2499 ± 0.0019 1.08 0.88 0.75 0.11 0.12 0.05
a Mean ± standard deviation for ﬁve determinations.
b % Relative standard deviation.
c % Relative error.
HPTLC methods for determination of antihypertensive mixtures 231Co-Dilatrol tablets (Chemipharm Pharmaceutical Industries
S.A.E., 6th October City, Egypt, Batch No. 110872A) and
Co-Dilatrend tablets (Roche Austria GmbH, Wien, Austria,
Batch No. M5015M1) labeled to contain 25 mg CRV and
12.5 mg HCT per tablet. Pharmaceutical preparation contain-
ing the three drugs is Exforge HCT tablets labeled to contain
10 mg AML, 320 mg VAL and 25 mg HCT (Novartis Pharma,
Switzerland). Analytical grade of ortho-phosphoric acid,
hydrochloric acid, ammonia and high purity distilled water
was used. Aluminum cards (20 · 20 cm), 0.2 mm thickness
with ﬂuorescent indicator at 254 nm Fluka Chemie GmbH,
and Sigma-aldrich Chemie GmbH, Buchs, Switzerland were
used.
2.3. General procedure and construction of calibration graphs
2.3.1. Preparation of stock and working solutions
Mix I: CRV 1000 lg/mL and HCT 1000 lg/mL stock solu-
tions were prepared in HPLC-grade methanol. The ﬁnal work-
ing solutions were prepared by diluting appropriate aliquots of
the stock solutions with HPLC grade methanol into two differ-
ent sets of 10-mL volumetric ﬂasks to reach the concentration
ranges of 5–100 and 10–200 lg/mL for CRV and HCT, respec-
tively. For Mix II: AML (1000 lg/mL), HCT (1000 lg/mL)
and VAL (2000 lg/mL) stock solutions were prepared in
HPLC-grade methanol. The ﬁnal working solutions were pre-
pared by diluting appropriate aliquots of the stock solutions
with HPLC grade methanol into three different sets of 10-
mL volumetric ﬂasks to reach the concentration ranges of
10–200, 20–400 and 10–200 lg/mL for AML, HCT and
VAL, respectively.2.3.2. Sample loading
The plates were ﬁrst activated at 90 C for 30 min, the solu-
tions were then applied to the marked start edge of the TLC
plate at a height of 15 mm from the lower edge of the plate
using the speciﬁed TLC CAMAG linomat syringe. The sample
volume for all solutions was 10 lL and spotting was performed
in the form of bands of 6-mm width and the spots were kept at
a constant distance of 7 mm from each other to avoid edge
effect. Each solution was applied in duplicate and allowed to
air-dry for 5 min.
2.3.3. Chromatogram development and scanning
The mobile phase used was chloroform–methanol in the vol-
ume ratio 8:2 v/v for mix I, while for Mix II the mobile phase
consists of chloroform–methanol–ammonia 8:2:0.1 v/v. The
TLC chamber was ﬁrst rinsed with the mobile phase, and then
15 mL of the mobile phase was poured in the chamber. The
chamber was covered with a lid and saturated for 30 min at
room temperature (25 ± 2 C). The sample-loaded TLC plates
were transferred to the chamber; Linear ascending develop-
ment of plates was carried out. Chromatogram run was kept
up to 80 mm. Spectrodensitometric analysis of the separated
components was carried out using Camag TLC Scanner using
deuterium/tungsten lamps set at 254 nm for both mixtures
except for AML the lamp was set at 365 nm. The slit dimen-
sion used was 4 · 0.45 mm and sensitivity was kept at auto
mode. Scanning speed was 20 mm/s.
2.3.4. Data processing
The dried plates were densitometrically scanned at the appro-
priate wavelengths. The TLC chromatogram was captured by
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232 R.A. Shaalan et al.the scanner and loaded into the CAMAG TLC software. Inte-
gration of the chromatogram was carried out using Planar
chromatography manager-win CATS (CAMAG).
In the software, the series of spots were selected as tracks.
Each track was evaluated based on the position of the spot
and its peak area. Quantity calibration was then performed
by pre assignment of the concentration of the investigated
drugs.
2.3.5. Preparation of sample solutions
MIX I: Ten tablets of each brand (Co-Dilatrol and Co-Dila-
trend) were weighed and average weight was calculated. An
amount of powdered tablets equivalent to 25 mg of CRV
and 12.5 mg of HCT from each brand was transferred into
two 100-mL volumetric ﬂasks with the aid of 50 mL methanol,
the solutions were stirred for 10 min then ﬁltered into 100-mL
calibrated ﬂasks. The residues were washed with 2 · 10 mL
methanol and washings were added to the ﬁltrates and diluted
to ﬁnal volume with methanol. MIX II: Ten Exforge HCT
tablets were weighed and ﬁnely powdered. HPLC-grade meth-
anol (30 mL) was added to a quantity of the powdered tablets
equivalent to 5 mg AML, 12.5 mg HCT, and 160 mg VAL, the
solution was stirred for 10 min then ﬁltered into a 50-mL cal-
ibrated ﬂask. The residue was washed with 2 · 5 mL methanol
and washings were added to the ﬁltrate and diluted to ﬁnal vol-
ume with methanol. Aliquots of the tablet solutions were
diluted with methanol to obtain ﬁnal concentrations within
the speciﬁed ranges then treated as under General Procedure
and recovered concentrations were calculated from the corre-
sponding calibration graphs. For standard addition assay,
sample solutions were spiked with aliquots of standard solu-
tions of each drug to obtain total concentrations within the
previously speciﬁed ranges then treated as under General Pro-
cedure. Recovered concentrations were calculated by compar-
ing the analyte response with the increment response attained
after addition of the standard.
2.4. Method validation
The proposed HPTLC methods were validated according to
the guidelines of the International Conference on Harmoniza-
tion (ICH).21 The linearities of the methods for the analyzed
drugs were checked between 0.05–1.0 lg/spot for CRV, 0.1–
2.0 lg/spot for HCT (in both mixtures), and AML, and 0.2–
4.0 lg/spot for VAL, ﬁnally concentration was plotted against
the peak area.
2.4.1. Accuracy
Accuracy, as recovery, was determined by the standard addi-
tion method. Preanalyzed samples of the analyzed drugs
(0.5 lg/spot) were spiked with extra standard solutions (0%,
50%, 100%, and 150%), and the mixtures were reanalyzed.
Percentage recovery and relative standard deviation (RSD,
%) were calculated for each concentration level.
2.4.2. Precision
Method repeatability was obtained from RSD values by
repeating the assay three times on the same day for inter-day
precision. Intermediate precision was assessed by the assay
of two sets on different days (inter-day precision). Intra- and
HPTLC methods for determination of antihypertensive mixtures 233inter-day variations by the proposed HPTLC methods were
carried out at three different concentration levels.
2.4.3. Robustness of the method
Robustness of the proposed TLC–densitometric methods was
determined to evaluate the inﬂuence of small deliberate
changes in the chromatographic conditions during determina-
tion of the cited drugs.
2.4.4. Limits of detection and quantiﬁcation
Limit of detection (LOD) and limit of quantiﬁcation (LOQ)
were determined by the signal to noise ratio method. The
LOD is deﬁned as the concentration that has a signal-to-noise
ratio of 3:1, while for LOQ the ratio is considered to be 10:1.
The minimum amount detected under the described chromato-
graphic conditions used was estimated.
2.4.5. Speciﬁcity
Speciﬁcity of the proposed TLC–densitometric methods was
conﬁrmed by analyzing and comparing the RF values and
spectra of the spots for the analyzed drugs in the samples with
those of the standards.
2.4.6. Quantiﬁcation of analyzed drugs in pharmaceutical
formulations and prepared mixtures of standard compounds
The test samples obtained from extraction of tablets or pre-
pared from standards in a concentration similar to that present
in formulations were applied, and chromatograms were
obtained under the same conditions as for the analysis of stan-
dard drugs. The area of the peak corresponding to the Rf value
of the drug standards was recorded. Recovered concentrations
were calculated from corresponding external standards. For
standard addition assay, sample solutions were spiked with ali-
quots of standard solutions of the drugs to obtain total con-
centrations within the previously speciﬁed ranges then
treated as under General Procedure. Recovered concentrationsFigure 5 Densitogram of Co-Dilatrend tablet contwere calculated by comparing the analyte response with the
increment response attained after addition of the standard.
3. Results and discussion
3.1. Optimization of chromatographic conditions
Chromatographic separation studies were carried out on the
standard solutions of CRV, HCT, AML, and VAL. Initially,
spots of standard solutions were applied on the plates. Plates
were developed by linear ascending development using neat
solvents like toluene, benzene, methanol, chloroform, ethyl
acetate, and acetone. Based on the results of these initial trials,
binary and ternary mixtures of solvents were tried to achieve
optimum resolution between the mentioned drugs in their
respective binary and ternary mixtures under investigation.
Accurate, precise, and reproducible results for simultaneous
determination of CRV and HCT in MIX I were obtained;
good separation of both drugs (Rf values of CRV
0.62 ± 0.06 and HCT 0.37 ± 0.03, respectively) with good
symmetrical peaks was obtained using the mobile phase, chlo-
roform:methanol (8:2, v/v). The separated spots of both drugs
were scanned at 254 nm. For Mix II, good separation of the
three drugs was obtained using the mobile phase, chloro-
form–methanol–ammonia 8:2:0.1 v/v. Acidiﬁcation of the
mobile phase using acetic acid was tried as well as alkaliniza-
tion using ammonia. Acidiﬁcation of the mobile phase using
acetic acid causes overlapping spots, while the use of ammonia
gives good resolved and compact spots. The concentration of
ammonia in the mobile phase was optimized and changed from
0.1 to 1.0 mL and it was found that 0.1 mL is quite enough.
Detection of spots was then performed at 254 nm for HCT
and VAL and at 365 nm for AML, where the latter drug shows
a broad absorption band suitable for its measurement. Other
chromatographic conditions like chamber saturation time,
run length, sample application rate and volume, sample appli-
cation positions, distance between tracks were optimized toaining 0.25 lg/spot CRV and 0.125 lg/spot HCT.
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peak shape for the studied drugs. The optimized chamber sat-
uration time for the mobile phase was found as 30 min at room
temperature (25 ± 2 C). The length of the chromatogram run
was approximately 80 mm. The spots appeared more compact
and the peak shape was more symmetrical when the TLC
plates were pre-treated and activated at 90 C for 30 min. After
development the plates were dried in air for 5 min. Slit dimen-
sion was 4 · 0.45 mm and the scanning speed was 20 mm/s.
Densitometric measurements were performed with a CAMAG
TLC Scanner 3 in the absorbance mode operated by CAMAG
TLC software. The optimized chromatographic conditions
gave compact spots for the cited drugs at the speciﬁc Rf values
mentioned in Table 1.AU
AU
Figure 6 Densitogram of Exforge-HCT tablet containing 0.1 lg/sp
and (B) 365 nm.3.2. Validation of the proposed method
Validation of the proposed methods was carried out in accor-
dance with the International Conference on Harmonization
(ICH) guidelines (2005).21
3.2.1. Linearity and concentration ranges
Linear correlations were obtained between peak area and con-
centration for each drug in the ranges speciﬁed in Table 1. 3D
chromatograms for the linearity sets prepared for the analyzed
drugs were presented as double spots in Figs. 2 and 3. Table 1
presents the performance data and statistical parameters
including linear regression equations, concentration ranges,
correlation coefﬁcients, standard deviations of the interceptB
Rf
A
Rf
ot AML, 0.25 lg/spot HCT, and 3.2 lg/spot VAL at (A) 254 nm
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Linearity of the calibration plots was conﬁrmed by the high
value of the correlation coefﬁcients (P0.9992). In addition, lin-
earity can be further evaluated by calculation of the RSD% of
the slope (Sb%) values, which did not exceed 2.04%.
3.2.2. Detection and quantiﬁcation limits
The sensitivity of the analytical methods was evaluated by
determining the LOD and LOQ. The LOD is deﬁned as the
concentration that has a signal-to-noise ratio of 3:1, while
for LOQ the ratio is considered to be 10:1. The minimum
amount detected under the described chromatographic condi-
tions used was estimated and listed in Table 1. The tabulated
values indicate that the methods have sufﬁcient sensitivity.
3.2.3. Accuracy and precision
The intra-day and inter-day precision of the proposed methods
were determined by estimating the corresponding responses
three times on the same day and on three different days for
three different concentrations. Testing of the intra-day and
inter-day precision in quantiﬁcation of the drugs showed that
the RSD% values were always less than 2% (Table 2) which
conﬁrm the high repeatability and intermediate precision of
the developed methods. Additionally, the Er% values were less
than 2%, which conﬁrms the accuracy of the proposed
methods.
3.2.4. Selectivity and speciﬁcity
The peak purity of analyzed drugs was assessed by comparing
their respective spectra at peak start, apex and end positions of
the peak (Fig. 4A–D). A good correlation (r value more thanTable 5 Application of the proposed HPTLC methods for determina
Co-Dilatrend tablets Results for external Standard Refer
CRV HCT CRV
% Recovery ± SDa 99.81 ± 0.50 100.13 ± 0.58 100.1
RSD%b 0.50 0.58 0.66
t 0.78 0.75
F 1.71 5.82
Co-Dilatrol tablets Results for external standard Refer
CRV HCT CRV
% Recovery ± SDa 99.84 ± 0.49 100.12 ± 0.59 99.56
RSD%b 0.49 0.59 0.53
t 0.86 1.80
F 1.17 3.61
Results for external standard Reference metho
Exforge
HCT
tablets
AML HCT VAL AML H
% Recovery
± SDa
99.55 ± 0.63 100.01 ± 0.51 99.32 ± 0.91 100.28 ± 1.12 99
RSD%b 0.63 0.51 0.92 1.12 0.9
t 1.26 0.71 1.93
F 3.23 3.23 1.45
Theoretical values for t and F at P= 0.05 are 2.31 and 6.39, respectively
a Mean ± standard deviation for ﬁve determinations.
b % Relative standard deviation.0.999) was obtained for all drugs. Acceptable peak purity
and correlation values suggest no interference in the quantiﬁ-
cation of the ﬁve analyzed drugs in sample solutions. This
proves that the methods are speciﬁc. Method selectivity was
further examined by preparing several laboratory-prepared
mixtures of the mentioned drugs at various concentrations
within the linearity ranges mentioned in Table 1. The labora-
tory-prepared mixtures were analyzed according to the pro-
posed procedure. The recovery values, RSD%, and Er%
values shown in Table 3 were satisfactory thus validating the
selectivity of the methods.
3.2.5. Robustness
The robustness of the methods was studied by performing
assays of cited drugs in pure form, and in tablet formulations.
The parameters of the optimized methods were deliberately
varied [plate source (Fluka or Merck), plate activation time
in the range of 30–50 min, plate activation temperature, cham-
ber saturation time from 15 to 45 min, and time elapsed until
scan], changes in the responses of the analyzed drugs were
noted and the assay values were calculated in the changed
parameters (Table 4). The methods proved to be robust,
because the assay and system suitability values in the changed
parameters were within the accepted range.
3.2.6. Stability of solutions
The stability of standard working solutions as well as sample
solutions in methanol was examined, and no chromatographic
changes were observed within 24 h at room temperature. Also,
the stock solutions prepared in HPLC-grade methanol were
stable for at least two weeks when kept at 4 C. Rf and spottion of the analyzed drugs in commercial pharmaceutical tablets.
ence method7 Standard addition
HCT CRV HCT
0 ± 0.66 99.92 ± 0.24 100.35 ± 0.60 100.11 ± 0.99
0.24 0.6 0.99
ence method7 Standard addition
HCT CRV HCT
± 0.53 99.10 ± 1.13 99.75 ± 0.31 99.89 ± 0.54
1.14 0.31 0.54
d18 Standard addition
CT VAL AML HCT VAL
.67 ± 0.93 100.56 ± 1.10 100.26 ± 0.78 100.01 ± 0.72 99.41 ± 0.56
3 1.09 0.78 0.72 0.56
.
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radation was observed during these periods.
3.3. Assay of tablet dosage forms
The developed HPTLC procedure was applied for the assay of
commercial drug combinations in different tablet brands. The
active ingredients eluted at their speciﬁc Rf values. No interfer-
ing peaks were observed from any of the inactive ingredients or
the dosage form matrix (Figs. 5 and 6). Recoveries were calcu-
lated using both external standard and standard addition
methods. The assay results revealed satisfactory accuracy
and precision as indicated from % recovery, SD, and RSD%
values (Table 5). The obtained results by the proposed meth-
ods were also statistically compared to those obtained by the
RP-HPLC reference methods7,18 using the Student’s t- and
the variance ratio F-tests. In both tests, the calculated values
did not exceed the theoretical ones at the 95% conﬁdence level
which indicated that there were no signiﬁcant differences
between the recoveries obtained from the developed method
and those of the reference method (Table 5). It is evident from
these results that the proposed methods are applicable for the
analysis of the cited active pharmaceuticals in their combined
commercial formulations with minimum sample preparation
and satisfactory level of selectivity, accuracy, and precision.
4. Conclusion
The developed HPTLC technique is precise, speciﬁc, and
accurate. The methods were simple and rapid, allowing a high
sample throughput necessary for quality control routine anal-
ysis with an added advantage of low solvent consumption.
The proposed methods were validated as per ICH guidelines,
and statistical analysis proves that the methods are repeatable
and selective for the analysis of the drugs in bulk form and in
pharmaceutical formulations without any interference from
the excipients. The standard deviations and RSD% calculated
for the methods are good, indicating a high degree of preci-
sion of the methods. The results of the recovery studies per-
formed show a high degree of accuracy of the proposed
methods. The methods can be used to determine the purity
of the drugs available from various sources by detecting the
related impurities and their respective Rf values. Moreover,
the proposed methods have the advantages of simplicity and
convenience.
To the best of our knowledge, the binary mixture of CRV
and HCT has been assayed by the TLC method in one recently
published report.8 Comparing our proposed method with this
report revealed that the proposed method is far more sensitive
than the reported method from the point of view of concentra-
tion range, LOD and LOQ. Also the mobile phase used in the
proposed method is a simpler binary solvent mixture. Two dif-
ferent tablet brands were assayed in this work to validate the
applicability of the proposed TLC method for the analysis of
pharmaceutical formulations. The precision was studied at
three different concentration levels covering the linearity range
and not only one concentration. Detailed statistical parameters
were provided as discussed in the ‘‘Linearity and concentration
ranges’’ and presented in Table 1. Comparing our proposed
method for the ternary mixture with the few HPTLC reports
found in the literature published in sound reputable journalsreveals that our proposed method is of comparable or even
better sensitivity and wider concentration ranges for determin-
ing the three drugs. The LOD of the proposed method are less
than those reported in the literature. The mobile phase used in
the study consisting of a binary mixture of chloroform and
methanol alkalinized with ammonia (0.1%) is considered more
simple and environment friendly than the mobile phases used
in the reported methods using ternary and quaternary solvent
combinations including ethyl acetate and methanol in addition
to chloroform, toluene and n-butyl acetate. Obviously, the
described HPTLC methods offer selectivity advantage over
the previously published spectrophotometric non-separation
methods. Moreover, the proposed methods do not require
elaborate treatment or sophisticated experimental setup usu-
ally associated with HPLC methods of analysis.
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